Leukemia: Artificial intelligence provides support in diagnostics

Decisions on treatment for patients with acute myeloid leukemia (AML)—a highly aggressive form of leukemia—are based, among other things, on a series of certain genetic features of the disease; but at the time when a diagnosis is made, this information is not available. Evidence of these genetic anomalies is crucial in providing targeted treatment for patients at an early stage. As genetic testing is expensive and time-consuming, there is a great need for inexpensive, fast and broadly accessible tests to predict such anomalies.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart